OXALIPLATIN HOSPIRA 5 MG/ML

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

OXALIPLATIN 5 MG/ML

MAH:

NOVAPHARMA LTD

ATC_code:

L01XA03

pharmaceutical_form:

CONCENTRATE FOR SOLUTION FOR INFUSION

administration_route:

I.V

manufactured_by:

HOSPIRA UK LTD

therapeutic_group:

OXALIPLATIN

therapeutic_indication:

In combination with 5- fluorouracil and folinic acid (FA) oxaliplatin is indicated for: - adjuvant treatment of stage III ( Duke's C) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

authorization_date:

2012-06-01